Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | DAO | P14920 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 3/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | PAK4 | O96013 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.38 |
| ▸ | LTK | P29376 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8483100 | 0.84 | DAO (0.61) | DAOAURKA | |
| SCHEMBL17365232 | 0.77 | BRD4 (0.46) | BRD4DAOACHEGDABRAF | |
| SCHEMBL3254704 | 0.77 | AURKA (0.46) | ACHEGDAAURKADAPK3JAK2 | |
| SCHEMBL19876250 | 0.76 | DAO (0.72) | BRD4DAOACHEGDABRAF | |
| SCHEMBL30663486 | 0.76 | DAO (0.72) | BRD4DAOACHEGDABRAF | |
| SCHEMBL23612486 | 0.76 | BRD4 (0.44) | BRD4DAOACHEGDABRAF | |
| SCHEMBL30663492 | 0.76 | DAO (0.72) | BRD4DAOACHEGDABRAF | |
| SCHEMBL16919105 | 0.76 | BRD4 (0.44) | BRD4DAOACHEGDABRAF | |
| SCHEMBL21895410 | 0.76 | AURKA (0.45) | BRD4DAOACHEGDABRAF | |
| SCHEMBL19876224 | 0.76 | DAO (0.72) | BRD4DAOACHEGDABRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227472-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230141101-A1 | PDE4 INHIBITOR COMPOUND AND MEDICAL USE THEREOF | SUZHOU LONGBOTAI PHARMACEUTICALS CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20220389029-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD (CN) | 2022-12-08 | — | — | US | disclosed |
| US-20220298174-A1 | TETRACYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD (CN) | 2022-09-22 | — | — | US | disclosed |
| US-11427580-B2 | 6-azaindole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-08-30 | — | — | US | disclosed |
| EP-4011886-A1 | TETRACYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) | 2022-06-15 | — | — | EP | disclosed |
| US-20210253593-A1 | SUBSTITUTED INDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-08-19 | — | — | US | disclosed |
| WO-2021052499-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海济煜医药科技有限公司 | 2021-03-25 | — | — | WO | disclosed |
| US-20210087174-A1 | ARYL AND HETEROARYL SUBSTITUTED INDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-03-25 | — | — | US | disclosed |
| WO-2021023154-A1 | TETRACYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海济煜医药科技有限公司 | 2021-02-11 | — | — | WO | disclosed |
| US-9062038-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20140228367-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | VIBLIOME THERAPEUTICS, LLC | 2014-08-14 | — | — | US | disclosed |
| US-20130267563-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-20130165464-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165472-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-7951819-B2 | Imidazo[4, 5-B]pyridin-2-one and oxazolo[4, 5-B] pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-05-31 | — | — | US | disclosed |
| WO-2011034741-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2011-03-24 | — | — | WO | disclosed |
| US-20090325945-A1 | IMIDAZO[4, 5-B]PYRIDIN-2-ONE AND OXAZOLO[4, 5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS CANCER THERAPEUTIC COMPOUNDS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2009-12-31 | — | — | US | disclosed |
| WO-2007125330-A1 | IMIDAZO[4, 5-B]PYRIDIN-2-ONE AND OXAZOLO[4, 5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS CANCER THERAPEUTIC COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165472-A1 | HETEROARYLS AND USES THEREOF | PIK3R4, VPS4B, PIK3C2A | BRD4 153/4885DAO 4741/4885ACHE 4391/4885 |
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | PIK3R5, PIK3R4, PIK3C2B | BRD4 323/4885DAO 4678/4885ACHE 4224/4885 |
| US-20220389029-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | KRAS, NRAS, WEE1 | BRD4 839/4885DAO 4229/4885ACHE 3856/4885 |
| US-20130267563-A1 | HETEROARYLS AND USES THEREOF | RICTOR, MTOR, AKT1S1 | BRD4 1026/4885DAO 4040/4885ACHE 4772/4885 |
| US-20230227472-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | KRAS, NRAS, WEE1 | BRD4 839/4885DAO 4229/4885ACHE 3856/4885 |
| US-20220298174-A1 | TETRACYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | KRAS, NRAS, HRAS | BRD4 3433/4885DAO 4261/4885ACHE 4680/4885 |
| US-20140228367-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | ABL1, ERBB2, MAP3K2 | BRD4 1132/4885DAO 2030/4885ACHE 4400/4885 |
| US-20230141101-A1 | PDE4 INHIBITOR COMPOUND AND MEDICAL USE THEREOF | PDE4B, PDE4A, PDE12 | BRD4 82/4885DAO 764/4885ACHE 858/4885 |
| US-20210087174-A1 | ARYL AND HETEROARYL SUBSTITUTED INDOLE COMPOUNDS | TLR7, TLR1, TLR9 | BRD4 513/4885DAO 1672/4885ACHE 3576/4885 |
| US-20090325945-A1 | IMIDAZO[4, 5-B]PYRIDIN-2-ONE AND OXAZOLO[4, 5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS CANCER THERAPEUTIC COMPOUNDS | NR2E1, NR0B1, NR2E3 | BRD4 104/4885DAO 2848/4885ACHE 4815/4885 |
| US-20130165464-A1 | HETEROARYLS AND USES THEREOF | PIK3C2B, PI4KB, PIK3R4 | BRD4 253/4885DAO 4695/4885ACHE 4074/4885 |
| US-20210253593-A1 | SUBSTITUTED INDOLE COMPOUNDS | TLR7, TLR1, HTR7 | BRD4 504/4885DAO 2797/4885ACHE 3543/4885 |
| US-11427580-B2 | 6-azaindole compounds | TLR7, TLR9, TLR5 | BRD4 959/4885DAO 1290/4885ACHE 2465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.